Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Carcinoma in Situ of Bladder”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 18 of 0 results

Not applicableUnknownNCT04770974
What this trial is testing

Urothelial Cancer Tumor Bio-markers and Physical-spectroscopic Characteristic

Who this might be right for
Urothelial CarcinomaBladder CancerUrothelial Neoplasm+2 more
University of Florence 200
Testing effectiveness (Phase 2)Looking for participantsNCT06833073
What this trial is testing

A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)

Who this might be right for
Urinary Bladder NeoplasmsNon-Muscle Invasive Bladder NeoplasmsCarcinoma in Situ
Merck Sharp & Dohme LLC 308
Large-scale testing (Phase 3)Study completedNCT00006034
What this trial is testing

Keyhole Limpet Hemocyanin Compared With Doxorubicin in Treating Patients With Bladder Cancer

Who this might be right for
Bladder Cancer
Intracel
Not applicableLooking for participantsNCT07614594
What this trial is testing

Non-invasive Urinary Genomics-Based Risk Assessment for Early Urothelial Carcinoma Diagnosis

Who this might be right for
Urothelial Carcinoma (UC)Upper Tract Urothelial CarcinomaUTUC+1 more
Henan Provincial People's Hospital 800
Testing effectiveness (Phase 2)Looking for participantsNCT04752722
What this trial is testing

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Who this might be right for
Superficial Bladder CancerNon-muscle Invasive Bladder Cancer With Carcinoma in SituNon-muscle Invasive Bladder Cancer
enGene, Inc. 350
Testing effectiveness (Phase 2)Active Not RecruitingNCT05241340
What this trial is testing

Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer

Who this might be right for
Urothelial Carcinoma Bladder
The Methodist Hospital Research Institute 33
Large-scale testing (Phase 3)Study completedNCT00052637
What this trial is testing

Cystoscopy and Hexyl 5-Aminolevulinate in Detecting Carcinoma In Situ in Patients With Bladder Cancer

Who this might be right for
Bladder Cancer
Photocure
Large-scale testing (Phase 3)Ended earlyNCT01438112
What this trial is testing

Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer

Who this might be right for
Transitional Cell CarcinomaBladder CancerCarcinoma in Situ+1 more
CG Oncology, Inc. 22
Testing effectiveness (Phase 2)Looking for participantsNCT07322263
What this trial is testing

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

Who this might be right for
Bladder CancerNon-Muscle Invasive Bladder Cancer (NMIBC)Urothelial Carcinoma+8 more
Michael A. O'Donnell 174
Not applicableLooking for participantsNCT04368702
What this trial is testing

CONFIRM: Magnetic Resonance Guided Radiation Therapy

Who this might be right for
Gastric CancerInvasive Breast Cancerin Situ Breast Cancer+3 more
Brigham and Women's Hospital 70
Large-scale testing (Phase 3)Looking for participantsNCT06545955
What this trial is testing

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

Who this might be right for
Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Ferring Pharmaceuticals 250
Testing effectiveness (Phase 2)Looking for participantsNCT03945162
What this trial is testing

Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

Who this might be right for
Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
Theralase® Technologies Inc. 90
Testing effectiveness (Phase 2)Study completedNCT04387461
What this trial is testing

Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin

Who this might be right for
Non Muscle Invasive Bladder Cancer
CG Oncology, Inc. 35
Testing effectiveness (Phase 2)Active Not RecruitingNCT04164082
What this trial is testing

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Who this might be right for
Bladder Flat Urothelial Carcinoma In SituNon-Muscle Invasive Bladder Urothelial CarcinomaStage 0a Bladder Cancer AJCC v8+2 more
National Cancer Institute (NCI) 161
Testing effectiveness (Phase 2)Ended earlyNCT02901548
What this trial is testing

Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder

Who this might be right for
Carcinoma in Situ of BladderBladder Cancer
H. Lee Moffitt Cancer Center and Research Institute 17
Early research (Phase 1)WithdrawnNCT03552796
What this trial is testing

SEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer

Who this might be right for
Recurrent Bladder CarcinomaBladder Cancer Stage 0Bladder Cancer Stage I
University of Southern California
Large-scale testing (Phase 3)Study completedNCT01316874
What this trial is testing

Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG)

Who this might be right for
Carcinoma in SituBladder Cancer
Endo USA Inc., a Keenova Therapeutics Company 90
Testing effectiveness (Phase 2)Study completedNCT00023842
What this trial is testing

BCG With or Without Mitomycin in Treating Patients With Bladder Cancer

Who this might be right for
Bladder Cancer
European Organisation for Research and Treatment of Cancer - EORTC 97